---
document_datetime: 2025-10-20 17:38:45
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/gardasil-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: gardasil-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.8159335
conversion_datetime: 2025-12-24 21:23:49.420363
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Gardasil

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproductlifecycleprocedures,youmayneed to alsorefer toEPAR-Procedural steps taken and scientific information after authorisation (archive).

| Applicationnumber   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|---------------------|-----------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Article 61(3) /     | -Notification acc.Article61(3)-Accepted | 20/10/2025                          |                                          | PL                              |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000307068                     | Update of the package leaflet with revised contactdetailsoflocalrepresentative and deletionof'UnitedKingdom(Northern Ireland)'fromthelistof local representatives inline with theQRD template v10.4.                                                                                                                                                                                                                                                                                |            |     |
|--------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation typeIB/ EMA/VR/0000278134  | This was an applicationfor a variation following a worksharing procedure according toArticle20ofCommissionRegulation(EC) No 1234/2008. B.I.a.1Change in the manufacturer of a startingmaterial/reagent/intermediateused inthemanufacturingprocessoftheactive substanceorchangeinthemanufacturer (includingwhererelevantqualitycontrol testingsites)oftheactivesubstance,where noPh.Eur.Certificate of Suitabilityispart of the approved dossier-B.I.a.1.z Other variation -Accepted | 16/10/2025 | N/A |
| Variation typeII / EMA/VR/0000278103 | Thiswas an applicationfor avariation followingaworksharingprocedureaccording toArticle20of CommissionRegulation(EC) No 1234/2008. B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.c Thechangereferstoabiological/                                                                                                                                                                                                                                    | 16/10/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | immunologicalsubstanceoruseofa differentchemicallyderivedsubstance in the manufactureofabiological/immunological substance,whichmayhaveasignificant impact on the quality, safety and efficacy of the medicinal product and is not related to a protocol - Accepted   |            |     |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000278523 | A.5Change in the name and/or address of a manufacturer/importer of the finished product(includingbatchreleaseor quality control testing sites)-A.5.bThe activities for which the manufacturer/importer is responsible do not include batch release - Accepted         | 08/08/2025 | N/A |